BackBarinthus Biotherapeutics Plc. Overview

Barinthus Biotherapeutics Plc. Intangible Assets

Latest intangible assets for BRNS: $13M.

Get informed when a big investor buys or sells

+ Follow
Intangible Assets
$13.04M
35.95% YoYΔ $-7.32M vs prior year quarter

Peer trimmed avg / median

Loading

Barinthus Biotherapeutics Plc. Intangible Assets History

Loading

Barinthus Biotherapeutics Plc. vs. peers: Intangible Assets Comparison

Loading

Barinthus Biotherapeutics Plc. Intangible Assets Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Barinthus Biotherapeutics Plc. (BRNS) FAQ

Barinthus Biotherapeutics Plc.'s intangible assets stands at $13M as of June 2026. That compares with $20M in the prior-year period — down 35.9% year over year. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

Barinthus Biotherapeutics Plc. reported $13M in intangible assets versus $20M a year earlier — a 35.9% year-over-year decrease. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

That compares with $20M in the prior-year period — down 35.9% year over year. Sustained growth in intangible assets can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.

The history chart shows how Barinthus Biotherapeutics Plc.'s intangible assets evolved across reporting periods, while the comparison chart places BRNS next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, intangible assets is commonly used to spot outliers. Barinthus Biotherapeutics Plc.'s reading of $13M is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.